Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

EBI2 overexpression in mice leads to B1 B-cell expansion and chronic lymphocytic leukemia-like B-cell malignancies.

Niss Arfelt K, Barington L, Benned-Jensen T, Kubale V, Kovalchuk AL, Daugvilaite V, Christensen JP, Thomsen AR, Egerod KL, Bassi MR, Spiess K, Schwartz TW, Wang H, Morse HC 3rd, Holst PJ, Rosenkilde MM.

Blood. 2017 Feb 16;129(7):866-878. doi: 10.1182/blood-2016-02-697185. Epub 2016 Dec 21.

PMID:
28003273
2.

Recent insights in the pathogenesis of post-transplantation lymphoproliferative disorders.

Morscio J, Tousseyn T.

World J Transplant. 2016 Sep 24;6(3):505-16. doi: 10.5500/wjt.v6.i3.505. Review.

3.

HLA Associations and Risk of Posttransplant Lymphoproliferative Disorder in a Danish Population-Based Cohort.

Vase MØ, Maksten EF, Strandhave C, Søndergaard E, Bendix K, Hamilton-Dutoit S, Andersen C, Møller MB, Sørensen SS, Kampmann J, Eiskjær H, Iversen M, Weinreich ID, Møller B, Jespersen B, d'Amore F.

Transplant Direct. 2015 Aug 11;1(7):e25. doi: 10.1097/TXD.0000000000000534. eCollection 2015 Aug.

4.

7α, 25-dihydroxycholesterol-mediated activation of EBI2 in immune regulation and diseases.

Sun S, Liu C.

Front Pharmacol. 2015 Mar 24;6:60. doi: 10.3389/fphar.2015.00060. eCollection 2015. Review.

5.

Oxysterol-EBI2 signaling in immune regulation and viral infection.

Daugvilaite V, Arfelt KN, Benned-Jensen T, Sailer AW, Rosenkilde MM.

Eur J Immunol. 2014 Jul;44(7):1904-12. doi: 10.1002/eji.201444493. Epub 2014 Jun 20. Review.

6.

Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways.

Kato H, Karube K, Yamamoto K, Takizawa J, Tsuzuki S, Yatabe Y, Kanda T, Katayama M, Ozawa Y, Ishitsuka K, Okamoto M, Kinoshita T, Ohshima K, Nakamura S, Morishima Y, Seto M.

Cancer Sci. 2014 May;105(5):537-44. doi: 10.1111/cas.12389. Epub 2014 Apr 9.

7.

Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era.

Gopal S, Patel MR, Yanik EL, Cole SR, Achenbach CJ, Napravnik S, Burkholder GA, Reid EG, Rodriguez B, Deeks SG, Mayer KH, Moore RD, Kitahata MM, Eron JJ, Richards KL.

J Natl Cancer Inst. 2013 Aug 21;105(16):1221-9. doi: 10.1093/jnci/djt158. Epub 2013 Jul 26.

8.

Small molecule antagonism of oxysterol-induced Epstein-Barr virus induced gene 2 (EBI2) activation.

Benned-Jensen T, Madsen CM, Arfelt KN, Smethurts C, Blanchard A, Jepras R, Rosenkilde MM.

FEBS Open Bio. 2013 Feb 19;3:156-60. doi: 10.1016/j.fob.2013.02.003. Print 2013.

9.

Association of early HIV viremia with mortality after HIV-associated lymphoma.

Gopal S, Patel MR, Yanik EL, Cole SR, Achenbach CJ, Napravnik S, Burkholder GA, Reid EG, Rodriguez B, Deeks SG, Mayer KH, Moore RD, Kitahata MM, Richards KL, Eron JJ.

AIDS. 2013 Sep 24;27(15):2365-73. doi: 10.1097/QAD.0b013e3283635232.

10.

Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?

Morscio J, Dierickx D, Tousseyn T.

Clin Dev Immunol. 2013;2013:150835. doi: 10.1155/2013/150835. Epub 2013 Apr 14. Review.

11.

In vivo functional requirement of the mouse Ifitm1 gene for germ cell development, interferon mediated immune response and somitogenesis.

Klymiuk I, Kenner L, Adler T, Busch DH, Boersma A, Irmler M, Fridrich B, Gailus-Durner V, Fuchs H, Leitner N, Müller M, Kühn R, Schlederer M, Treise I, de Angelis MH, Beckers J.

PLoS One. 2012;7(10):e44609. doi: 10.1371/journal.pone.0044609. Epub 2012 Oct 24. Erratum in: PLoS One. 2012;7(11):doi/10.1371/annotation/e53f8ba4-8e00-45ec-a051-e48d003f278a. Fridrich, Barbara [added].

12.

Posttransplant lymphoproliferative disorders.

Ibrahim HA, Naresh KN.

Adv Hematol. 2012;2012:230173. doi: 10.1155/2012/230173. Epub 2012 Apr 17.

13.

Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model.

Zhang B, Kracker S, Yasuda T, Casola S, Vanneman M, Hömig-Hölzel C, Wang Z, Derudder E, Li S, Chakraborty T, Cotter SE, Koyama S, Currie T, Freeman GJ, Kutok JL, Rodig SJ, Dranoff G, Rajewsky K.

Cell. 2012 Feb 17;148(4):739-51. doi: 10.1016/j.cell.2011.12.031.

14.

Deletion of Kaposi's sarcoma-associated herpesvirus FLICE inhibitory protein, vFLIP, from the viral genome compromises the activation of STAT1-responsive cellular genes and spindle cell formation in endothelial cells.

Alkharsah KR, Singh VV, Bosco R, Santag S, Grundhoff A, Konrad A, Stürzl M, Wirth D, Dittrich-Breiholz O, Kracht M, Schulz TF.

J Virol. 2011 Oct;85(19):10375-88. doi: 10.1128/JVI.00226-11. Epub 2011 Jul 27.

15.

Ligand modulation of the Epstein-Barr virus-induced seven-transmembrane receptor EBI2: identification of a potent and efficacious inverse agonist.

Benned-Jensen T, Smethurst C, Holst PJ, Page KR, Sauls H, Sivertsen B, Schwartz TW, Blanchard A, Jepras R, Rosenkilde MM.

J Biol Chem. 2011 Aug 19;286(33):29292-302. doi: 10.1074/jbc.M110.196345. Epub 2011 Jun 14.

16.

Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Gulley ML, Tang W.

Clin Microbiol Rev. 2010 Apr;23(2):350-66. doi: 10.1128/CMR.00006-09. Review.

17.

Epstein-Barr virus, rapamycin, and host immune responses.

Krams SM, Martinez OM.

Curr Opin Organ Transplant. 2008 Dec;13(6):563-8. doi: 10.1097/MOT.0b013e3283186ba9. Review.

Supplemental Content

Support Center